New Analysis Suggests Whole Diet Approach to Lower Cardiovascular Risk Has More Evidence Than Low-Fat Diets
Philadelphia, PA, February 5, 2014
diets most successful, reports The American Journal of Medicine
Mediterranean-style diets most successful, reports The American Journal of Medicine
A study published in The
American Journal of Medicine reveals that a whole diet approach, which
focuses on increased intake of fruits, vegetables, nuts, and fish, has more
evidence for reducing cardiovascular risk than strategies that focus exclusively
on reduced dietary fat. This new study explains that while strictly low-fat
diets have the ability to lower cholesterol, they are not as conclusive in
reducing cardiac deaths. By analyzing major diet and heart disease studies
conducted over the last several decades, investigators found that participants
directed to adopt a whole diet approach instead of limiting fat intake had a
greater reduction in cardiovascular death and non-fatal myocardial infarction.
Early investigations of the relationship between food and heart disease linked high levels of serum cholesterol to increased intake of saturated fat, and subsequently, an increased rate of coronary heart disease. This led to the American Heart Association's recommendation to limit fat intake to less than 30% of daily calories, saturated fat to 10%, and cholesterol to less than 300 mg per day.
"Nearly all clinical trials in the 1960s, 70s and 80s compared usual diets to those characterized by low total fat, low saturated fat, low dietary cholesterol, and increased polyunsaturated fats," says study co-author James E. Dalen, MD, MPH, Weil Foundation, and University of Arizona College of Medicine. "These diets did reduce cholesterol levels. However they did not reduce the incidence of myocardial infarction or coronary heart disease deaths."
Carefully analyzing studies and trials from 1957 to the present, investigators found that the whole diet approach, and specifically Mediterranean-style diets, are effective in preventing heart disease, even though they may not lower total serum or LDL cholesterol. The Mediterranean-style diet is low in animal products and saturated fat, and encourages intake of monounsaturated fats found in nuts and olive oil. In particular, the diet emphasizes consumption of vegetables, fruit, legumes, whole grains, and fish.
"The potency of combining individual cardioprotective foods is substantial – and perhaps even stronger than many of the medications and procedures that have been the focus of modern cardiology," explains co-author Stephen Devries, MD, FACC, Gaples Institute for Integrative Cardiology (Deerfield, IL) and Division of Cardiology, Northwestern University (Chicago, IL). "Results from trials emphasizing dietary fat reduction were a disappointment, prompting subsequent studies incorporating a whole diet approach with a more nuanced recommendation for fat intake."
Based on the data from several influential studies, which are reviewed in the article, Dalen and Devries concluded that emphasizing certain food groups, while encouraging people to decrease others, is more cardioprotective and overall better at preventing heart disease than a blanket low-fat diet. Encouraging the consumption of olive oil over butter and cream, while increasing the amount of vegetables, fruits, whole grains, nuts, and fish promises to be more effective.
"The last fifty years of epidemiology and clinical trials have established a clear link between diet, atherosclerosis, and cardiovascular events," concludes Dr. Dalen. "Nutritional interventions have proven that a 'whole diet' approach with equal attention to what is consumed as well as what is excluded is more effective in preventing cardiovascular disease than low fat, low cholesterol diets."
# # #
Notes for editors
"Diets to Prevent Coronary Heart Disease 1957 – 2013: What Have We Learned?" by James E. Dalen, MD, MPH; Stephen Devries, MD, FACC (DOI: 10.1016/j.amjmed.2013.12.014), appears in The American Journal of Medicine, published by Elsevier.
Full text of the article is available to credentialed journalists upon request. Contact Jane Grochowski at +1 215 239 3712 or email@example.com to obtain copies. Journalists wishing to interview the authors should contact Dr. Dalen at firstname.lastname@example.org or Dr. Devries at Integrate@GaplesInstitute.org.
About The American Journal of Medicine
The American Journal of Medicine (http://www.amjmed.com), known as the "Green Journal," is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 4.768, which ranks it 13 out of 151 General and Internal Medicine titles according to the 2012 Journal Citation Reports® published by Thomson Reuters.
AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 215 239 3712